Chemed President, CEO Sold Shares Worth Over $1M

Chemed Corp. CEO Kevin J. McNamara sold 2,000 shares at an average price of $537.90, totaling $1,075,800. He now directly owns 82,220 shares, according to an SEC filing.

Original reporting
Published Nov 5, 2026, 8:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 8:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Chemed President, CEO Sold Shares Worth Over $1M — source image
Decision brief

The 30-second read

Low
01

Why it matters

Insider selling often precedes short‑term price weakness, but the magnitude is modest relative to float.

02

Market read

The filing is a primary source of new information that may influence short‑term trading decisions on CHMD.

03

What to watch

Potential tax planning or liquidity needs for the executive are not disclosed.

Relevance 5/10Novelty 6/10Timing: today

Background

Chemed Corp (NASDAQ:CHMD) provides specialized health care services. The filing shows the CEO reduced his stake.

Market effects

Minimal impact on the healthcare services sector; the sale is company‑specific.

No broader regional effect; confined to Chemed investors.

Limited to U.S. investors tracking insider activity.

Counterpoint

The sale could be a routine portfolio rebalancing rather than a negative signal.

Key entities

  • Kevin J. McNamara

    President, CEO, and director of Chemed Corp.

Related articles

$CHEMedAI 9/10

Chemed 3Q 2026: Revenue $690.9M, EPS $5.45— 10-Q Summary

Chemed reported Q3 2026 revenue of $690.9M, up 10.6% YoY, with net income rising 11.5% to $71.6M and EPS increasing 22.2% to $5.45. Growth in VITAS and Roto-Rooter segments drove results, while higher fuel costs pressured margins. The company acquired RotoCo and other franchises, expanding its territories.

$CHEMed

What Chemed (CHE) Said on Its Q3 Earnings Call

Chemed reported Q3 earnings, with Roto-Rooter revenue up 7.5% but EBITDA down 2.5% due to higher costs. Commercial revenue grew 9% to $59.9M, while residential rose 5.2% to $158.8M. The company acquired California franchises for $62.5M, expecting $30M-$35M in 2027 revenue but less than $4M in EBITDA. Chemed repurchased 125,000 shares for $66M. Management expects 2026 EPS to meet or slightly exceed guidance.

$CHEMed

Chemed outlines 12- to 18-month integration timeline for $62.5M California Roto-Rooter franchise buyback while expecting 2026 EPS at or slightly above prior high end (NYSE:CHE)

Chemed (CHE) announced a 12- to 18-month integration timeline for its $62.5M California Roto-Rooter franchise buyback. CEO Kevin McNamara reported VITAS revenue grew 12.2% year-over-year, driven by ADC growth and cost containment. The company expects 2026 EPS to be at or slightly above the prior high end.

$CHEHighAI 8/10

Chemed (CHE) Q3 2026 Earnings Call Transcript

Chemed (CHE) reported Q3 2026 earnings with total revenue up 10.6% and adjusted EPS up 28.1% YoY. VITAS saw 12.2% revenue growth, while Roto Rooter grew 7.5%. Roto Rooter's margins declined due to higher marketing costs and fuel expenses, but acquisitions are expected to drive long-term growth. The company has $229M in cash flow from operations, enabling strategic acquisitions and share repurchases.

$CHEHighAI 8/10

Why is Chemed stock surging today?

Chemed (CHE) stock rose 9.2% after Q3 earnings beat estimates, with adjusted EPS of $6.75 and revenue of $690.9M. VITAS hospice division showed strong growth. Jefferies upgraded the stock to Buy, raising its price target to $620. Bank of America also increased its target to $555. The stock hit a 52-week high.